What
image
  • imageAdvertising & Marketing
  • imageAutomotive
  • imageBusiness Dealerships
  • imageBusiness Services
  • imageEducation
  • imageFood & Beverage
  • imageHealth & Beauty
  • imageHome Based
  • imageHome Services
  • imageOthers
  • imagePet
  • imageRetail
  • imageTravel & Leisure
Where
image
image
At a glance
10K - 50K
Investment Range
251 - 500
Franchise Count
101 - 500 sq.ft
Area Required
18 - 24 months
Payback Period
Less than 1
Years in Franchising

About the brand

Medizia Biotech Franchise

Brand & Franchise Snapshot

Brand Name Medizia Biotech
Industry Pharmaceutical Manufacturing
Business Category Pharmacies / PCD Pharma Distribution
Founded Year 2018
Franchise Started Operates through PCD pharma distribution model
Total Franchise Outlets 200–500
Estimated Investment INR 10,000 – 50,000
Franchise Fee Typically part of product purchase and distribution rights in PCD models
Royalty Fee Generally not applicable in PCD pharma; earnings are margin-based
Space Requirement 100 – 200 sq. ft.
Staff Requirement Basic distribution handling staff or self-operated
Expected Payback Period 1–2 Years

1. What is Medizia Biotech?

Medizia Biotech is a pharmaceutical manufacturing and distribution company focused on injectable formulations used in critical care treatments. It operates in the PCD pharma franchise segment, supplying medicines to distributors who market and sell products within assigned territories to healthcare providers and pharmacies.

2. How the Business Works

The business follows a manufacturing-to-distribution model. The company develops and produces injectable medicines, which are supplied to franchise partners.

Distributors promote these products to doctors, hospitals, and pharmacies in their territory. Orders are placed based on demand, and revenue is generated through product sales margins rather than service fees. The workflow centers on supply chain coordination, product promotion, and order fulfillment.

3. Products or Services Offered

The product portfolio focuses on pharmaceutical injectables, particularly in critical care:

  • Antibiotic Injections (infection management)
  • Cardiology Injectables (heart-related conditions)
  • Gastroenterology Injectables (digestive system treatments)
  • Antimalarial Injections (infectious disease management)
  • Analgesics and NSAIDs (pain management solutions)

These products are designed for hospital and clinical usage rather than over-the-counter retail.

4. Franchise Structure and Operating Model

  • Franchise partners operate as PCD distributors in assigned territories
  • Responsible for marketing, sales, and relationship building with healthcare providers
  • Products are supplied by the company under agreed terms
  • Partners typically receive territory-based distribution rights
  • Revenue depends on product margins and sales volume

This model emphasizes sales execution and local market penetration rather than operating a retail outlet.

5. Franchise Cost and Investment

Estimated Investment: INR 10,000 – 50,000

In PCD pharma models, the investment mainly covers initial product inventory and marketing materials. A traditional franchise fee may not apply, as costs are embedded in product procurement.

There is generally no royalty; earnings come from the difference between purchase and selling price of medicines.

6. Space and Setup Requirements

Space Requirement 100–200 sq. ft.
Location Preference Areas with access to pharmacies, clinics, and hospitals
Infrastructure Needs Storage for pharmaceutical products, basic inventory system
Staffing Can be self-managed or supported by a small sales team

The setup is lightweight compared to retail pharmacies or clinics.

7. Training and Franchise Support

Support systems typically include:

  • Product knowledge training for pharmaceutical formulations
  • Marketing materials and promotional inputs
  • Guidance on regulatory and compliance aspects
  • Assistance with order management and supply chain coordination

These systems help distributors operate effectively within regulated healthcare markets.

8. Revenue Model and ROI Factors

Revenue is driven by:

  • Product sales margins across pharmaceutical categories
  • Repeat orders from doctors, hospitals, and pharmacies
  • Expansion of distribution networks within assigned territories

Demand is influenced by healthcare needs, hospital usage, and prescription patterns. The payback period depends on sales volume growth and consistent client relationships.

9. Brand Background and Expansion

Established in 2018, the company focuses on injectable pharmaceutical manufacturing with a growing distribution network. With several hundred franchise partners, expansion is driven through territory-based distributors across multiple regions and markets.

10. What Makes This Franchise Different

The business is centered on injectable formulations for critical care, a segment that differs from general pharmaceutical distribution. These products are typically used in hospitals and emergency settings, which creates demand driven by clinical necessity rather than consumer retail behavior. This shifts the focus toward institutional sales and medical relationships.

11. Key Advantages of the Franchise

  • Demand driven by healthcare and hospital requirements
  • Low initial investment compared to other pharma businesses
  • Scalable distribution model across territories
  • Repeat demand from medical professionals
  • Support in product supply and marketing materials

12. Who Should Consider This Franchise

  • Individuals with experience in pharmaceutical sales
  • Medical representatives or healthcare distributors
  • Entrepreneurs interested in pharma distribution businesses
  • Small investors seeking low-investment entry into healthcare sector

14. Similar Franchise Opportunities

  • Mankind Pharma
  • Cipla
  • Sun Pharma
  • Alkem Laboratories
  • Zydus Lifesciences
Health & Beauty Pharmacies B2C Owner-Operated Individual

Investment and financials

Cost overview
Investment range10K - 50K
Franchise / Brand feeAvailable on inquiry
Royalty / CommissionAvailable on inquiry
Investment tierLow
Area required101 - 500 sq.ft
Staff required2 - 6
Setup complexityModerate
Renewal availableYes
Returns outlook
Expected monthly revenue
Available on inquiry
Revenue levelLow
Business modelB2C
Capital payback18 - 24 months
Capital sensitivityVery High

Investor fit profile

Operations
Operation modeOwner-Operated
Location typeResidential/High Street
Home-based possibleNo
Can run part-timeNo
Primary customerIndividual
Market characteristics
SeasonalityVery High
Recession resistanceHigh
Digital integrationHigh
Years in franchisingLess than 1
Ideal for
Homemaker Student Salaried Professional seeking side income Pharmacist

Franchise support

Training and agreement details
Renewal available
Yes

Brand strength

Less than 1
Years Franchising
Available on inquiry
Founded
C
Brand Tier
C
Tier C — Startup brand
A+Established AMature BGrowing CStartup
Startup

Forefind rank history

#28#36#44#522020202120222023202420252020: #302021: #342022: #402023: #462024: #552025: #47
Current rank
#47
#47 of 120 in Pharmacies
2025
Moved down 17 places since 2020
Based on Forefind scoring model

Licences and compliance

Required licences and registrations for operating this franchise in India. Requirements may vary by state and city tier.
Drug License
GST
Setup complexity: Moderate

Frequently asked questions

The investment typically ranges from INR 10,000 to 50,000. This amount is primarily used for purchasing initial stock and marketing materials. Unlike traditional franchises, the investment is inventory-driven rather than infrastructure-heavy, making it accessible for small-scale distributors.

The business operates through a distribution model where partners promote and sell pharmaceutical injectables within a designated territory. Revenue is generated through margins on product sales, with a focus on building relationships with doctors, hospitals, and pharmacies.

A small storage and operational space of around 100 to 200 sq. ft. is sufficient. The business does not require a retail storefront, as sales are primarily conducted through direct interaction with healthcare professionals and institutions.

The expected payback period is approximately 1 to 2 years. Recovery depends on sales performance, territory coverage, and the ability to secure repeat orders from healthcare providers and institutional buyers.

Investors can apply by contacting the company to obtain distribution rights. The process generally involves selecting a territory, completing registration formalities, purchasing initial inventory, and starting sales operations with support from the company. ## 14. Similar Franchise Opportunities

Disclaimer: All scores, rankings, and estimates on ForeFind are independently produced editorial assessments using publicly available data and validated brand-submitted information. They are not verified facts, financial advice, or investment recommendations. Full Disclaimer.

image